Carbon Monoxide Therapy Using Hybrid Carbon Monoxide-Releasing/Nrf2-Inducing Molecules through a Neuroprotective Lens
Abstract
Carbon monoxide (CO) has long been known for its toxicity. However, in recent decades, new applications for CO as a therapeutic compound have been proposed, and multiple forms of CO therapy have since been developed and studied. Previous research has found that CO has a role as a gasotransmitter and promotes anti-inflammatory and antioxidant effects, making it an avenue of interest for medicine. Such effects are possible because of the Nrf2/HO1 pathway, which has become a target for therapy development because its activation also leads to CO release. Currently, different forms of treatment involving CO include inhaled CO (iCO), carbon monoxide-releasing molecules (CORMs), and hybrid carbon monoxide-releasing molecules (HYCOs). In this article, we review the progression of CO studies to develop possible therapies, the possible mechanisms involved in the effects of CO, and the current forms of therapy using CO.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 23, 2021
- Source ID
- 10.3390/chemistry3030057
Entities
People
- Flavia Cavicchioli
- Izzy M. Cesarotti
- Josh Lua
- Madison Fangman
- Raymond C. Hautamaki
- Sylvain Doré
Organizations
- National Institutes of Health
- United States Department of Defense